Does breast carcinoma in situ require chemotherapy?

Every woman should pay great attention to her breasts, because there are quite a few people with breast cancer in modern society, and severe breast cancer can spread to other areas of the body, which can have a great impact on the patient's health. However, there are many types of breast cancer, and each type should be treated with different treatments. So does breast carcinoma in situ require chemotherapy?

Breast cancer is divided into many pathological types. Breast carcinoma in situ is the pathological type with the best prognosis. Generally, chemotherapy is not required and surgery can achieve the purpose of radical cure. The decision whether to perform endocrine therapy to prevent recurrence on the other side is mainly based on the pathological results after surgery. Because breast carcinoma in situ has the risk of causing contralateral breast cancer, it is recommended to do a good job of follow-up examinations and regularly perform breast ultrasound and mammography examinations. If there is any doubt, early surgical treatment is recommended. Breast carcinoma in situ is hormone receptor positive and may require endocrine therapy, but no other treatment is needed.

The latest data show that the 10-year mortality rate of ductal carcinoma in situ of the breast is only 1.1%, and the 20-year mortality rate is only 3.3%. That is to say, out of 100 patients with breast ductal carcinoma in situ, 97 of them can basically be completely cured through current treatment.

Moreover, the chance of distant metastasis of carcinoma in situ is very small, only 1%. In contrast, the risk of recurrence and metastasis of invasive cancer is much higher, and it is an important cause of death in breast cancer patients.

However, based on the nuclear grade of the cancer cells, ductal carcinoma in situ can also be divided into low-risk, intermediate-risk and high-risk types. The risk of recurrence and metastasis of high-risk carcinoma in situ is much higher than that of medium- and low-risk ones. Even so, the prognosis for high-risk DIS remains good with treatment.

As for low-risk carcinoma in situ, if the patients are older and more resistant to surgery or medication, they may not even have to pay attention to it and just observe it for a long time and follow up regularly.

Therefore, if you are unfortunately diagnosed with ductal carcinoma in situ, there is no need to be nervous, because its prognosis is very good and it will not affect your life expectancy in most cases. You just need to communicate well with your doctor and work together to develop a treatment plan that suits you.